Terbinafine, a new orally allylamine derivative antifungal agen, is compared to itraconazole in patients with tinea pedis. Sixty-six patients with mycologically (microscopy and culture) proven tinea pedis were enrolled in this study (terbinafine
group
33, itrconzole group 33) . Terbinafine was givent at 250mg once daily for 2 weeks and itraconazole was given at 100mg once daily for 4 weeks. Of these, 44 patients were evvaluable for drug efficacy(terbinafine group 22, itraconazole group 22.).
Using
the scores (absent=0, mild=1, moderate=2, severe=3), clinical signs and symptoms were assessed weekly for 4 weeks in both group, Mycological culture and microscopy (KOH) were carried out at the end of therapy and 2 weeks later in terbinafine
group,
and
every 2weeks during therapy in itraconazole group. at 2 weeks, five of twenty-two(22.7%) of terbinafine group and 4 of 22(18.1%) itraconazole group were mycologically negative (microscopy or culture). Fourteen of twenty-two(63.6%) of terbnafine
group
and 15 of 22(68.1%) of itraconazole group were negative at 4 weeks. Clinical sings and symptoms improved but there was no statistical difference between terbinafine and itraconazole group, Mycological and clinical results were simillar in both
itraconazole group. Mycolgcial and clinical results were simillar in both group and this results we suggest possibility of short term therapy of terbinafine in tinea pedis.
|